What is Keros Therapeutics, Inc. (KROS)?

Keros Therapeutics, Inc. (KROS) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of KROS?

The current price of KROS is $11.36. Prices are updated in real time on Stocks360.

What is KROS's price-to-earnings (PE) ratio?

KROS's trailing twelve-month PE ratio is -3.07, based on current price and earnings per share data available on Stocks360.

What is KROS's market capitalization?

KROS's market capitalization is $225,236,856.00, placing it in the small-cap tier.

Keros Therapeutics, Inc. (KROS)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$11.36

Market Cap

$225.24M

PE (TTM)

-3.07

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.02

Day Range

$11.21 – $11.88

52-wk Range

$9.69 – $22.55

Avg Volume

N/A

Volume

205.02K

Keros Therapeutics, Inc. (KROS) is a publicly traded company in the Healthcare sector. Latest price: $11.36. Market cap $225.24M. Trailing PE -3.07. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

You have viewed 4 SEO analysis pages

Unlock saved watchlists, personalized setups, and referral credits with a free Stocks360 account.

Continue with free signup

1-Year Price

2025-10-30 · $15.03 2026-10-29 · $11.36 (-24.42%)

Earnings

Most Recent

Aug 3, 2026

EPS $-1.45 vs est. $-1.34

Missed by $0.11

Next Earnings

Nov 4, 2026

EPS estimate $-0.96

Proprietary Signals

Signal snapshot temporarily unavailable.

About Keros Therapeutics, Inc.

Keros Therapeutics, Inc., a biopharmaceutical entity in the clinical development phase, is focused on pioneering and commercializing innovative therapies for individuals afflicted by hematological and musculoskeletal conditions that currently lack adequate treatment options. Its flagship protein therapeutic, KER-050, is being advanced to address diminished blood cell counts (cytopenias), specifically anemia and thrombocytopenia, in patients diagnosed with myelodysplastic syndromes and myelofibrosis. Furthermore, the company is progressing KER-047, a small molecule designed to combat anemia, which is presently undergoing Phase 1 clinical evaluation. Another small molecule, KER-012, is also in Phase 1 clinical trials for treating ailments characterized by bone degeneration, such as osteoporosis and osteogenesis imperfecta, alongside pulmonary arterial hypertension. Founded in 2015, the firm maintains its principal operations in Lexington, Massachusetts.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-3.07×
P/S (TTM)	15.00×
P/B	0.86×
PEG	0.00×
P/FCF (TTM)	-4.65×
EV / EBITDA	0.20×
EV / Sales	-1.11×
Earnings Yield	-36.97%
Free Cash Flow Yield	-21.53%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$16.65M
Net Income (TTM)	-$83.27M
Free Cash Flow (TTM)	-$48.49M
Net Debt	-$241.88M
Working Capital	$254.73M
Gross Margin	94.68%
Operating Margin	-675.82%
Net Margin	-553.88%
Return on Equity	-21.40%
Return on Invested Capital	-35.25%